Can a new drug combo flush out hidden HIV?

NCT ID NCT07053384

Ongoing Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether adding an experimental drug (VH3810109) with or without another drug (fostemsavir) to standard HIV therapy can reduce the hidden viral reservoir in people living with HIV. About 107 adults, either new to treatment or already on stable therapy, will participate. The goal is to see if these combinations can lower the amount of inactive HIV hiding in cells, which is a key step toward better long-term control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Bakersfield, California, 93301, United States
GSK Investigational Site

San Diego, California, 92103, United States
GSK Investigational Site

Ft. Pierce, Florida, 34982, United States
GSK Investigational Site

Orlando, Florida, 32803, United States
GSK Investigational Site

Chicago, Illinois, 60611, United States
GSK Investigational Site

Kansas City, Missouri, 64111, United States
GSK Investigational Site

St Louis, Missouri, 63110, United States
GSK Investigational Site

New York, New York, 10032, United States
GSK Investigational Site

Cincinnati, Ohio, 45267, United States
GSK Investigational Site

Philadelphia, Pennsylvania, 19104, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15213, United States
GSK Investigational Site

Dallas, Texas, 75208, United States
GSK Investigational Site

Dallas, Texas, 75246, United States
GSK Investigational Site

Brussels, 1000, Belgium
GSK Investigational Site

Ghent, 9000, Belgium
GSK Investigational Site

Aarhus, 8200, Denmark
GSK Investigational Site

Hvidovre, 2650, Denmark
GSK Investigational Site

Rotterdam, 3015 GD, Netherlands
GSK Investigational Site

Barcelona, 08003, Spain
GSK Investigational Site

Barcelona, 08026, Spain
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Barcelona, 08036, Spain
GSK Investigational Site

Barcelona, 08916, Spain
GSK Investigational Site

Barcelona, 8907, Spain
GSK Investigational Site

Córdoba, 14004, Spain
GSK Investigational Site

La Laguna Santa Cruz, 38320, Spain
GSK Investigational Site

Madrid, 28020, Spain
GSK Investigational Site

Madrid, 28031, Spain
GSK Investigational Site

Madrid, 28034, Spain
GSK Investigational Site

Madrid, 28040, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Madrid, 28046, Spain
GSK Investigational Site

Madrid, 28224, Spain
GSK Investigational Site

Palma de Mallorca, 07120, Spain
GSK Investigational Site

Palma de Mallorca, 7198, Spain
GSK Investigational Site

Seville, 41013, Spain
GSK Investigational Site

Valencia, 46014, Spain
GSK Investigational Site

Valencia, 46026, Spain
GSK Investigational Site

London, NW3 2QG, United Kingdom
GSK Investigational Site

London, SE1 7EH, United Kingdom
GSK Investigational Site

London, W2 1NY, United Kingdom